Amplification and/or activation of the c-Myc proto-oncogene is one of the leading genetic events along hepatocarcinogenesis. The oncogenic potential of c-Myc has been proven experimentally by the finding that its overexpression in the mouse liver triggers tumor formation. However, the molecular mechanism whereby c-Myc exerts its oncogenic activity in the liver remains poorly understood. Here, we demonstrate that the mammalian target of rapamycin complex 1 (mTORC1) cascade is activated and necessary for c-Myc-dependent hepatocarcinogenesis. Specifically, we found that ablation of Raptor, the unique member of mTORC1, strongly inhibits c-Myc liver tumor formation. Also, the p70 ribosomal S6 kinase/ribosomal protein S6 and eukaryotic translation initiation factor 4E-binding protein 1/eukaryotic translation initiation factor 4E signaling cascades downstream of mTORC1 are required for c-Myc-driven tumorigenesis. Intriguingly, microarray expression analysis revealed up-regulation of multiple amino acid transporters, including solute carrier family 1 member A5 (SLC1A5) and SLC7A6, leading to robust uptake of amino acids, including glutamine, into c-Myc tumor cells. Subsequent functional studies showed that amino acids are critical for activation of mTORC1 as their inhibition suppressed mTORC1 in c-Myc tumor cells. In human hepatocellular carcinoma specimens, levels of c-Myc directly correlate with those of mTORC1 activation as well as of SLC1A5 and SLC7A6. Conclusion: Our current study indicates that an intact mTORC1 axis is required for c-Myc-driven hepatocarcinogenesis; thus, targeting the mTOR pathway or amino acid transporters may be an effective and novel therapeutic option for the treatment of hepatocellular carcinoma with activated c-Myc signaling. (HEPATOLOGY 2017;66:167-181). L iver cancer is the fifth most common cancer in men and the ninth in women and the second most common cause of cancer death worldwide.
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(1) Both incidence and mortality rates of liver cancer are rising. (2) Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Liver resection, liver transplantation, and interventional radiology are still the main therapies for HCC; but they can Abbreviations: ChIP, chromatin immunoprecipitation; 4EBP1, eukaryotic translation initiation factor 4E-binding protein 1; eIF4E, eukaryotic translation initiation factor 4E; HCC, hepatocellular carcinoma; mTOR, mammalian target of rapamycin; mTORC1/2, mTOR complexes 1 and 2; pCMV-SB, phosphorylated cytomegalovirus-sleeping beauty; p70S6K, p70 ribosomal S6 kinase; RPS6, ribosomal protein S6; sh-, short hairpin; SLC1A5, solute carrier family 1 member A5.
solely be applied in the early stage of the disease. (3) In addition, treatment with the multi-tyrosine kinase inhibitor sorafenib, the only targeted therapy approved for advanced HCC, provides almost negligible benefits in terms of patient prognosis. (4) Recent advances in the understanding of the molecular pathogenesis of HCC have provided novel biomarkers for disease stratification and targets for treatment. (5, 6) Among the putative candidates for targeted therapies in HCC is c-Myc, a well-characterized oncogene. (7) c-Myc is a transcriptional factor that contributes to malignant transformation and tumor progression by regulating the expression of a plethora of genes involved in cell growth, metabolism, and carcinogenesis. (8) In human HCC, c-Myc is frequently overexpressed and amplified, and its levels directly correlate with poor prognosis. (9, 10) The oncogenic potential of cMyc in the liver is underscored by the finding that its overexpression is sufficient to induce HCC formation in mice. (11, 12) However, the molecular mechanisms underlying c-Myc-driven hepatocarcinogenesis remain poorly delineated.
Activation of the mammalian target of rapamycin (mTOR) pathway is another critical molecular event in tumorigenesis. (13) mTOR is comprised of two distinct complexes, namely, complex 1 and complex 2 (mTORC1 and mTORC2). (13) mTORC1, with Raptor as its unique and key protein component, is a major regulator of cell growth, metabolism, and survival. (13) mTORC1 functions by regulating the p70 ribosomal S6 kinase (p70S6K)/ribosomal protein S6 (RPS6) and eukaryotic translation initiation factor 4E-binding protein 1/eukaryotic translation initiation factor 4E (4EBP1/eIF4E) downstream cascades. (13) mTORC2, with Rictor as its unique and key protein component, functions instead by modulating the AGC family kinases, including AKT, protein kinase C, and the serum/ glucocorticoid-regulated kinases. (14) Similar to c-Myc, the mTOR cascade is often deregulated in human HCC and may represent a novel and promising target for HCC treatment. (15) In agreement with this hypothesis, it has been found that over half of HCC cases display activated mTOR signaling. (16) Also, mTOR inhibitors have been shown to effectively inhibit HCC cell growth. (17) Furthermore, we recently found that mTOR is essential for hepatocarcinogenesis driven by activated AKT and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha 3CA proto-oncogenes in the mouse. (18) (19) (20) (21) While both the c-Myc and mTOR pathways have been independently implicated in hepatocarcinogenesis, the possible biochemical crosstalk between the two signaling cascades has not been characterized. In the present study, we show that the mTOR pathway is activated along hepatocarcinogenesis driven by c-Myc overexpression in mice. Importantly, ablation of mTORC1 completely inhibited c-Myc HCC development in mice, with both S6K/RPS6 and 4EBP1/ eIF4E cascades being necessary for c-Myc-induced hepatocarcinogenesis. In addition, we found that
c-Myc induces mTORC1 activation through the upregulation of multiple amino acid transporters, including solute carrier family 1 member A5 (SLC1A5) and SLC7A6, in mouse and human HCC. Altogether, the present findings open the possibility for new therapeutic strategies against HCC, at least for the tumor subset characterized by activation of the c-Myc oncogene.
Materials and Methods

PLASMIDS AND REAGENTS
The plasmids used for the study, including pT3EF1a-c-Myc, pT3EF1a-4EBP1WT, pT3EF1a-4EBP1A4, and phosphorylated cytomegalovirussleeping beauty (pCMV-SB) have been described in our previous publications. (12, 20) To delete Raptor while coexpressing c-Myc into the mouse liver, short hairpin Raptor (shRaptor; against mouse Raptor; Addgene 21399) or shLuc (against Renilla luciferase) sequences were cloned at the c-terminal of c-Myc to generated pT3EF1a-c-Myc-shLuc and pT3EF1a-c-MycshRaptor constructs using a standard molecular cloning approach. Rapamycin was purchased from LC Laboratories (Woburn, MA).
HYDRODYNAMIC INJECTION AND MOUSE TREATMENT
FVB/N mice were purchased from Jackson Laboratory (Bar Harbor, ME). AKT2 knockout mice were kindly provided by Dr. Morris J. Birnbaum (University of Pennsylvania) and have been described. (21) Sleeping beauty-mediated hydrodynamic injections were performed as described. (22) In brief, mice were hydrodynamically injected with pT3EF1a-c-Myc (20 lg) and pCMV-SB (0.8 lg). To determine the requirement of mTORC1 in c-Myc-driven liver tumor development, mice were injected with pT3EF1a-c-Myc-shLuc (20 lg) or pT3EF1a-c-Myc-shRaptor (20 lg) together with pCMV-SB (0.8 lg). For blocking the mTORC1 pathway, rapamycin, which efficiently blocks the S6K/ RPS6 cascade, was intraperitoneally injected in a dose of 6 mg/kg/day for 6 days a week starting 3 weeks after hydrodynamic injection of the c-Myc construct. Additional cohorts of mice were injected intraperitoneally with vehicle (PEG400 and Tween 80) as the control group. To elucidate the functional role of the 4EBP1/ eIF4E pathway, either 40 lg of pT3EF1a-4EBP1A4 (the unphosphorylatable form of 4EBP1) or 40 lg of pT3EF1a-4EBP1WT (wild-type 4EBP1) were coinjected with pT3EF1a-c-Myc (8 lg) together with pCMV-SB (1.96 lg). All mice were monitored closely and euthanized as described. Mice were fed and monitored according to protocols approved by the Committee for Animal Research at the University of California-San Francisco.
HUMAN TISSUE SAMPLES
A collection of formalin-fixed, paraffin-embedded HCC (n 5 88) samples was used in the present study. Sixty-four frozen HCC and corresponding nontumorous surrounding livers from the same collection were also used. The clinicopathological features of liver cancer patients are summarized in Supporting Table S1 . HCC specimens were collected at the medical universities of Greifswald (Greifswald, Germany), Rome La Sapienza (Pietro Valdoni Surgery Department, Rome, Italy), and Sassari (Sassari, Italy). Institutional review board approval was obtained from the local ethics committee of the medical universities of Greifswald, Rome, and Sassari. Informed consent was obtained from all subjects.
STATISTICAL ANALYSIS
GraphPad Prism, version 6.0 (GraphPad Software Inc., La Jolla, CA), was used to evaluate statistical significance by the Tukey-Kramer, Student t, and MannWhitney tests and linear regression analyses. Overall survival was estimated according to Kaplan-Meier and log-rank (Mantel-Cox) tests. Univariate and multivariate Cox analyses were used to estimate hazard ratios for risk factors using STATA 9 statistical software (Stata Corporation, College Station, TX). Values of P < 0.05 were considered significant. Data are expressed as mean 6 standard error of the mean for each group. A two-tailed unpaired t test was used to compare the differences between two groups.
A detailed description of materials and methods is supplied as Supporting Information.
Results
THE mTORC1 PATHWAY IS ACTIVATED AND REQUIRED FOR c-Myc-DEPENDENT HEPATOCARCINOGENESIS
In accordance with previous data, (12, 23) hydrodynamic gene delivery of the c-Myc oncogene into the mouse liver resulted in a lethal burden of liver cancer by 6 weeks postinjection (Fig. 1) . To investigate the possible crosstalk between the c-Myc and mTOR pathways in hepatocarcinogenesis, we evaluated the status of mTOR in c-Myc mouse tumor tissues. Of note, we found that downstream effectors of mTORC1 (p-RPS6 and p-4EBP1) as well as of mTORC2 (p-AKTS473) were up-regulated in c-Myc tumor samples (Fig. 1B,C) , thus implying that the mTOR cascade is activated along c-Myc hepatocarcinogenesis.
Raptor is the unique and essential subunit of mTORC1. (13) To investigate whether mTORC1 is required for c-Myc-driven hepatocarcinogenesis, we applied microRNA-30-based shRNA to silence Raptor while coexpressing c-Myc in the mouse liver ( Fig. 2A) . In brief, the shRNA sequence against mouse Raptor or Renilla luciferase (18) was cloned downstream of c-Myc in a pT3-EF1a vector (c-Myc-shRaptor or c-MycshLuc); subsequently, the plasmids were hydrodynamically injected into mice. Studies from our and other labs have demonstrated that the shRaptor sequence is effective in silencing Raptor expression (24) in mouse cells, including in mouse liver cells. (18) As expected, all cMyc-shLuc-injected mice developed a lethal tumor burden and had to be euthanized within 6-7 weeks postinjection. In striking contrast, none of the c-MycshRaptor-injected mice developed HCC up to 12.3 weeks postinjection (Fig. 2B,C) . Histological evaluation confirmed the lack of neoplastic lesions in c-MycshRaptor livers (Fig. 2D) . Altogether, the present results indicate that mTORC1 is activated and required for c-Myc-induced liver tumor formation in mice.
RAPAMYCIN TREATMENT EFFECTIVELY INHIBITS c-Myc-INDUCED HEPATOCARCINOGEN-ESIS IN THE EARLY STAGE
mTORC1 functions through p70S6K/RPS6 and 4EBP1/eIF4E cascades. (25) First, we assessed whether 
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p70S6K/RPS6 is a key mTORC1 downstream effector in c-Myc tumor development. Our and other investigations have demonstrated that rapamycin is a partial mTORC1 inhibitor as it effectively inhibits the p70S6K/RPS6 axis without affecting 4EBP1/eIF4E signaling. (20) Thus, we subjected c-Myc mice to rapamycin treatment. Specifically, c-Myc was hydrodynamically injected into mice. Three weeks postinjection, when the tumors start to emerge, (11) c-Myc mice were treated with rapamycin or vehicle for an additional 3 weeks (Fig. 3A) . While all vehicle-treated mice became moribund due to the high tumor burden, none of the rapamycin-treated mice developed a palpable liver mass. Upon dissection, only small tumor nodules were visible on the liver of rapamycin-treated mice (Fig. 3C ), leading to a significantly lower liver weight when compared with vehicle-treated mice (Fig.  3B) . Histologically, the small lesions from rapamycintreated mice were identical to those from untreated or vehicle-treated mice (Fig. 3C ). Immunostaining demonstrated expression of c-Myc in the tumor lesions and that tumor cells were proliferating, as revealed by Ki67 staining (Fig. 3D) . At the molecular level, as reported, (26) rapamycin treatment induced the inhibition of p70S6K/pRPS6, with limited effects on p-4EBP1/eIF4E (Fig. 3E ). We next determined whether rapamycin is effective in inhibiting c-Myc HCC cell growth in vitro. We used HCC3-4 and HCC4-4 mouse liver tumor cell lines, which were derived from c-Myc transgenic mice. (27) We found that rapamycin effectively suppressed the growth of HCC3-4 and HCC4-4 with a 50% inhibitory concentration of around 25 lM (Supporting Fig. S1A ). Consistently, rapamycin treatment strongly inhibited p70S6K/pRPS6 in the two Myc HCC cell lines (Supporting Fig. S1B ).
In summary, rapamycin effectively inhibits c-Mycinduced hepatocarcinogenesis through inhibition of the S6K/RPS6 axis.
INHIBITION OF 4EBP1/eIF4E DELAYS BUT DOES NOT SUPPRESS c-Myc-INDUCED HEPATOCARCINOGENESIS
Next, we investigated whether the 4EBP1/eIF4E cascade is required for c-Myc-induced hepatocarcinogenesis. Thus, we coinjected c-Myc with 4EBP1A4, the unphosphorylatable form of 4EBP1 (20) (c-Myc/ 4EBP1A4), or 4EBP1 wild type (c-Myc/4EBP1WT) into mice. It is important to note that 4EBP1WT can still be phosphorylated by the endogenous mTORC1, preventing it from binding to eIF4E. Therefore, 4EBP1WT remains inactive although overexpressed. In contrast, the 4EBP1A4 mutant form, with T37, T46, S65, and T70 being replaced by alanine, cannot be phosphorylated and, thus, continuously binds to eIF4E. (28) 4EBP1A4 functions to inhibit eIF4E-mediated cap-dependent translation downstream of mTORC1. (28) We found that by 6.7 weeks postinjection all c-Myc/4EBP1WT mice developed a lethal burden of liver tumors. In contrast, all c-Myc/ 4EBP1A4 mice appeared to be healthy with no palpable abdominal mass at this time point. Upon dissection, a few small nodules could be found in the liver of c-Myc/4EBP1A4 mice. Large tumors were instead detected in c-Myc/4EBP1A4 mice by 10-14.2 weeks postinjection ( Fig. 4A-C) .
Histological evaluation demonstrated that liver tumor nodules from c-Myc/4EBP1A4 mice were similar to those that developed in c-Myc/4EBP1WT-injected and c-Myc-only-injected mice (Fig. 4D) . At the molecular level, ectopically injected hemagglutinintagged 4EBP1WT and 4EBP1A4 constructs could be readily detected within the tumor lesions (Fig. 4E) .
Thus, our study indicates that 4EBP1/eIF4E is a key downstream effector of mTORC1 whose inhibition delays, but cannot completely block, c-Mycinduced hepatocarcinogenesis.
As neither rapamycin nor 4EBP1A4 was able to completely prevent c-Myc tumorigenesis in vivo, we inhibited the two cascades simultaneously by injecting the mice with c-Myc/4EBP1A4 plasmid and treating them with rapamycin, starting 4 weeks post-hydrodynamic injection (Fig. 5A) . Noticeably, combined 4EBP1A4 and rapamycin treatment completely inhibited c-Myc-driven hepatocarcinogenesis (Fig. 5B-D) , thus recapitulating the effects of Raptor knockdown in c-Myc-overexpressing livers (Fig. 2) .
c-Myc-DRIVEN HEPATOCARCINOGENESIS IS INDEPENDENT OF AKT2, THE MAJOR AKT ISOFORM IN THE LIVER
mTORC1 is well characterized as being activated by the insulin/phosphoinositide 3-kinase/AKT pathway in the liver. Thus, we investigated whether c-Mycinduced hepatocarcinogenesis depends on AKT2, the major AKT isoform downstream of insulin signaling in the liver. In a previous study, we showed that loss of AKT2 completely abolishes the oncogenic potential of activated phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha in mice. (21) To determine the requirement of AKT2 for c-Myc-dependent hepatocarcinogenesis, we injected c-Myc into AKT2 -/-mice or control AKT2 1/1 littermates (Supporting Fig.  S2A) . Surprisingly, we found that in both cohorts of mice, liver tumor developed at the same rate and latency. Indeed, by 6 weeks postinjection, all c-Mycinjected AKT2 -/-or control AKT2 1/1 mice developed a lethal burden of liver tumors (Supporting Fig. S2B) . LIU, GE, ET AL. HEPATOLOGY, July 2017 AKT2 1/1 genetic background were undistinguishable (Supporting Fig. S2C) . At the molecular level, western blotting demonstrated that AKT2 was successfully knocked out in AKT2 -/-c-Myc liver tumor tissues (Supporting Fig. S2D ). In addition, p-AKT(S473) levels were higher in AKT2 1/1 c-Myc tumor tissues than in AKT2 -/-c-Myc corresponding lesions. Furthermore, p-RPS6 and p-4EBP1 expression was similar in AKT2 -/-and AKT2 1/1 mouse liver lesions. Altogether, our study strongly suggests that c-Mycinduced mTORC1 activation and tumorigenesis is independent of AKT2.
AMINO ACIDS ARE MAJOR FACTORS PROMOTING mTORC1 ACTIVATION ALONG c-Myc HEPATOCARCINOGENESIS
To further explore the mechanisms whereby mTORC1 becomes activated following c-Myc overexpression, we performed transcriptomic analysis of normal liver and c-Myc liver tumor tissues. Intriguingly, we found that multiple members of the amino acid transporter families (SLC 1, 7, 36, and 38 families) were up-regulated in c-Myc liver tumors (Fig.  6A) . Based on these preliminary findings, we next determined the expression of SLC family transporters in HCC3-4 and HCC4-4 mouse liver tumor cell lines using quantitative RT-PCR. Of note, we found that SLC1A5, SLC7A6, SLC7A1, SLC7A3, SLC7A5, SLC36A2, and SLC1A1 mRNAs were markedly higher in HCC3-4 and HCC4-4 liver tumor cells than in primary hepatocytes (*P < 0.05, **P < 0.01, ***P < 0.001; Fig. 6B; Supporting Fig.  S3 ). Based on mRNA expression patterns, SLC1A5 and SLC7A6 appear to be the major SLC family amino acid transporters in c-Myc liver tumor cells. Western blotting confirmed that protein levels of SLC1A5 and SLC7A6 were significantly upregulated in HCC3-4 and HCC4-4 c-Myc liver tumor cell lines when compared with primary hepatocytes (Fig. 6C) .
Subsequently, we investigated whether upregulation of amino acid transporters leads to increased amino acid uptake into c-Myc liver tumor cells. For this purpose, we analyzed the uptake rate of 20 amino acids in primary mouse hepatocytes and c-Myc liver tumor cells. We found that among the 20 amino acids glutamine showed the most drastic increase, with high amounts taken up by primary hepatocytes, HCC3-4 cells, and HCC4-4 cells compared with their controls without adding amino acids ( Fig. 6D; Supporting Fig.  S4 ). Also, increased uptake of isoleucine, tyrosine, methionine, threonine, and alanine was detected (Supporting Fig. S4 ) Amino acids are known to be able to activate mTORC1. (29, 30) Thus, we tested the hypothesis that amino acids are the major regulators of mTORC1 in c-Myc tumors. For this purpose, we evaluated the effects of amino acids on mTOR activity in c-Myc HCC cell lines. Notably, we found that deprivation of amino acids in the culture medium strongly inhibited mTOR activity in HCC3-4 and HCC4-4 cells, as determined by p-4EBP1, p-RPS6, and p-P70S6K expression (Fig. 7A) . Adding amino acids back to the culture medium rescued the expression of p-4EBP1, p-RPS6, and p-P70S6K in c-Myc cells (Fig. 7A) . Similar results were obtained in six human HCC cell lines which display high levels of c-Myc (Supporting Fig. S5 ). Next, we determined whether SLC1A5 and SLC7A6 are the major amino acid transporters regulating mTORC1 signaling in c-Myc tumor cells. Strikingly, efficient knockdown of SLC1A5 and SLC7A6 expression (Fig. 7B ) resulted in decreased uptake of glutamine (Fig. 7D ) and reduced mTORC1 activity (Fig. 7B ) in c-Myc liver tumor cell lines. Subsequently, treatment with L-c-glutamyl-p-nitroanilide, a glutamine analogue and inhibitor of amino acid transporters, strongly inhibited glutamine uptake into c-Myc HCC cell lines. Once again, the inhibition of amino acid transporters was paralleled by a decline of mTORC1 activity in HCC3-4 and HCC4-4 cells (Fig. 7C) .
Based on this body of evidence, we investigated whether SLC1A5 and SLC7A6 are direct transcriptional targets of c-Myc in liver tumors. Toward this goal we analyzed the public chromatin immunoprecipitation (ChIP) sequencing data (GSE76078) from the liver-specific c-Myc transgenic mouse model. (31) Importantly, ChIP sequencing data show that Myc binds SLC1A5 and SLC7A6 in the promoter region together with RNA polymerase II holoenzyme as well as active histone markers H3K4me3 and H3K27ac in the c-Myc transgenic liver tumor samples (Supporting Fig. S6A ). Next, we examined the effects of c-Myc silencing on the expression of SLC1A5 and SLC7A6. Quantitative RT-PCR analysis confirmed that the small interfering RNA used against human c-Myc significantly reduced the expression levels of c-Myc (Supporting Fig. S7A ) as well as SLC1A5 and SLC7A6 in HCC3-4 and HCC4-4 cells (Supporting Fig. S7B) . Knockdown of c-Myc also decreased the uptake of glutamine in HCC3-4 and HCC4-4 cells compared with that from control small interfering RNA transfected cells (Supporting Fig. S7C ). Finally, to verify the public ChIP sequencing results, we performed ChIP-quantitative PCR to examine the occupancy of c-Myc to the promoter regions of the SLC1A5 and SLC7A6 genes. Consistently, anti-c-Myc ChIP showed significant enrichment over the SLC1A5 and SLC7A6 promoter regions in both HCC3-4 and HCC4-4 cells when compared with those of cells immunoprecipitated with normal immunoglobulin G antibody as negative controls (Supporting Fig. S6B) .
Altogether, the present data indicate that c-Myc directly up-regulates the expression of SLC1A5 and SLC7A6 transporters, thus resulting in increased uptake of amino acids, which in turn leads to mTORC1 activation and eventual liver tumor formation (Supporting Fig. S8 ).
LEVELS OF c-Myc CORRELATE WITH THOSE OF mTORC1 ACTIVATION AND SLC1A5/SLC7A6 IN HUMAN HCC PATIENTS
Finally, we evaluated the relationship of c-Myc with the mTORC1 cascade as well as the SLC1A5 and SLC7A6 genes in a collection of human HCC specimens. First, levels of c-Myc, p-RPS6, and p-4EBP1 were determined in a collection of human HCC specimens (n 5 88) by immunohistochemistry (Fig. 8A) . Higher immunoreactivity for c-Myc, p-RPS6, and p-4EBP1 proteins was detected in 56.8%, 54.5%, and 47.7% of HCC specimens, respectively, when compared with surrounding nontumorous liver tissues. Importantly, 38 HCC specimens showing c-Myc upregulation also exhibited elevated levels of p-RPS6 and p-4EBP1. The Pearson correlation coefficient between c-Myc and p-RPS6 was 0.524 (P < 0.0001), whereas that between c-Myc and p-4EBP1 was 0.626 (P < 0.0001) (Fig. 8B) . In addition, all HCC samples exhibiting c-Myc amplification (21/88; 23.9%) displayed elevated immunoreactivity for p-RPS6 and p-4EBP1. Subsequently, we evaluated the mRNA levels of c-Myc in the HCC samples whose clinicopathological data were available (n 5 64; Supporting Table S1 ).
We found that c-Myc mRNA levels were significantly higher in HCC with poorer prognosis when compared to those with better prognosis. Similarly, mTORC1 activity was highest in HCC specimens with unfavorable outcome. Of note, a highly significant correlation between c-Myc mRNA levels and mTORC1 activity was detected in the HCC collection (P < 0.0001; Fig.  8C ). Subsequently, we evaluated the relationship between c-Myc and SLC1A5/SLC7A6 mRNA levels. Notably, expression levels of SLC1A5 and SLC7A6 were weakly but statistically significantly correlated with those of c-Myc (P 5 0.0002 and P 5 0.0017, respectively; Supporting Fig. S9A ). This weak but statistically significant correlation between c-Myc and SLC1A5/SLC7A6 mRNA expression was validated using The Cancer Genome Atlas data set (Supporting Fig. S9B ). Furthermore, high expression of c-Myc, SLC1A5, and SLC7A6 correlated with a lower HCC survival rate, and this association remained significant after multivariate Cox regression analysis (P < 0.01; Supporting Table S2 ), suggesting that they are independent prognostic factors for HCC. Kaplan-Meier analysis confirmed this finding for SLC1A5 (P 5 0.004) and SLC7A6 (P < 0.0001) (Supporting Fig.  S10) . No relationship between the mRNA levels of cMyc, SLC1A5, and SLC7A6 and other clinicopathological features of the patients, including age, gender, etiology, presence of cirrhosis, tumor size, and tumor grade, were detected (Supporting Table S2 ).
Altogether, the present data indicate that human HCC with high c-Myc levels is characterized by elevated activity of mTORC1 and up-regulation of SLC1A5 and SLC7A6 gene expression.
Discussion
Both the c-Myc and mTOR pathways have been implicated in tumorigenesis, and the biochemical crosstalk between the two pathways has been found to play a critical role during tumor growth. For instance, it has been shown that c-Myc directly up-regulates transcription of the eIF4E proto-oncogene, whose activity is tightly regulated by phosphorylated 4EBP1 downstream of mTORC1. (32) In addition, c-Myc has been identified as a direct target of mTOR, (33) and 4EBP1/eIF4E modulates the translation levels of cMyc. (34) Also, using a c-Myc-driven mouse model of B-cell lymphoma, Pourdehnad et al. showed that the mTOR-dependent 4EBP1/eIF4E axis confers survival to c-Myc lymphoma cells. (35) However, whether the mTOR and c-Myc cascades functionally interact to promote hepatocarcinogenesis has not been elucidated to date.
In this study, we show that the mTOR pathway is induced in c-Myc liver tumor cells and that activated mTORC1 is required for c-Myc tumor development in vivo. In addition, using pharmacological and genetic approaches, we demonstrate that both the p70S6K/ RPS6 and 4EBP1/eIF4E cascades downstream of mTORC1 have key roles along c-Myc-dependent tumorigenesis. Furthermore, a strong association between c-Myc levels and mTORC1 activity was detected in a collection of human HCC specimens, thus indicating that the functional crosstalk between cMyc and mTORC1 is conserved across species. Our study therefore provides a critical link between the two oncogenic pathways in hepatocarcinogenesis. The signaling and metabolic pathways downstream of p70S6K/RPS6 and 4EBP1/eIF4E clearly require further investigation. Studies have shown that fatty acid synthase and its mediated de novo lipogenesis is a major metabolic pathway downstream of p70S6K/ RPS6 during tumor development. (36, 37) In accordance with these findings, preliminary data from our group indicate that levels of fatty acid synthase and acetylcoenzyme A carboxylase lipogenic proteins are upregulated in c-Myc liver tumor samples (L. Che, unpublished results). Further studies are ongoing to determine whether the deregulated fatty acid metabolism pathway is the major event downstream of the p70S6K/RPS6 cascade in c-Myc mice.
Further analysis showed that c-Myc up-regulates the expression of multiple amino acid transporters, including SLC1A5 and SLC7A6. They belong to the SLC group of membrane transport proteins, which includes over 300 members. (38) These transporters facilitate the transport of large numbers of substrates across the cell membrane and have critical roles in various physiological and pathological processes. (38) Expression of amino acid transporters has been reported to be up-regulated in human cancer cells, and their increase facilitates the uptake of amino acids that are required for tumor cell growth. (39) Among all the amino acid transporters, SLC1A5 is the most studied. For instance, recent studies showed that SLC1A5 controls glutamine uptake and proliferation in breast cancer cells, (40) and targeting SLC1A5 efficiently decreases the growth of non-small cell lung cancer. (41) The functional contribution of SLC7A6 during tumorigenesis is not well characterized. A study suggests that SCL7A6 is an androgen-responsive gene that is required for the growth of metastatic castrationresistant prostate cancer. (42) Reports on the role of amino acid transporters in HCC and the mechanisms whereby they contribute to hepatocarcinogenesis are scanty. Here, we show that c-Myc directly upregulates SLC1A5 and SLC7A6, leading to increased uptake of amino acids to the cells and activation of the mTOR cascade. Therefore, SLC1A5 and SLC7A6 are the major amino acid transporters and determinants of mTOR activity along c-Myc-driven liver tumorigenesis. In our study, we show that a weak but statistically significant correlation between c-Myc mRNA expression with SLC1A5 and SLC7A6 in human HCCs exists using both our sample set and The Cancer Genome Atlas data set (Supporting Fig.  S9 ). There are several possible reasons for the weak association. First, it is most likely that SLC1A5 and SLC7A6 expression is regulated by multiple factors during hepatocarcinogenesis, and c-Myc is only one of these factors. For instance, the serine/threonine kinases serum/glucocorticoid-regulated kinase 1 and serum/ glucocorticoid-regulated kinase 3 were found to induce SLC1A5 expression. (43) Second, mRNA expression may not accurately reflect the eventual protein levels and, thus, the activity of the gene. Concerning c-Myc, it has been clearly demonstrated that the protein stability can be modulated through proteolysis as well as phosphorylation. (44) It is clearly important to further study the correlation between c-Myc and SLC1A5/ SLC7A6 at the protein as well as the posttranslational modification levels in human HCC samples.
The present study has several important translational implications. First, our data support the use of mTOR inhibitors for the treatment of HCC with high levels of c-Myc. Recent clinical studies showed that treatment with everolimus, an mTORC1 inhibitor, did not improve overall survival in patients with advanced HCC. (45) However, a biomarker-based selection of patients with HCC who may truly benefit from mTOR inhibition was not conducted in the clinical trial. It is plausible to hypothesize that the use of c-Myc expression as a biomarker of mTOR activation may enrich HCC patients who may benefit from treatment with mTOR inhibitors. Another important issue that might explain the failure of the aforementioned clinical trial is the fact that everolimus is a partial mTORC1 inhibitor as it only inhibits the p70S6K/RPS6 cascade but does not affect the 4EBP1/ eIF4E axis. Based on the present and our previous study, (20) the 4EBP1/eIF4E branch of mTORC1 also plays a critical role in hepatocarcinogenesis, and the lack of 4EBP1/eIF4E inhibition might strongly limit everolimus's efficacy in HCC patients. Therefore, the use of pan-mTOR inhibitors, such as MLN0128 or AZD8055, should be tested in HCC patients.
In addition to mTOR, SLC membrane transporters have been identified as valid druggable targets (38, 46) because small molecules or antibodies may block the membrane transporters and, thus, inhibit the uptake of substrates. Many US Food and Drug Administrationapproved drugs function primarily through the inhibition of SLC transporters, such as diuretic drugs that target SLC12 and neuropsychiatric drugs targeting SLC6. (38) Many efforts have been made to develop drugs that can target amino acid transporters for cancer treatment. (39) Among them, several drugs, including benzylserine and L-c-glutamyl-p-nitroanilide, have been shown to efficiently inhibit SLC1A5. (39) Obviously, additional studies are required to develop more efficient drugs targeting amino acid transporters as well as to determine whether these drugs can efficiently inhibit tumor growth in vivo. Nevertheless, our study strongly supports targeting amino acid transporters as a therapeutic strategy at least in the subset of HCCs with elevated c-Myc expression. In this regard, the c
